Health and Healthcare

AstraZeneca's FDA Nod Could Be Big

courtesy of the U.S. Food and Drug Administration

AstraZeneca PLC (NYSE: AZN) has announced that the U.S. Food and Drug Administration (FDA) has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.

Specifically, the approval is for BRACAnalysis CDx for use as a companion diagnostic test by health care professionals to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor Lynparza (olaparib).

Currently, BRACAnalysis CDx is the first and only FDA-approved genetic test for this indication.

Pancreatic cancer is the third most common cause of cancer-related death in the United States, and germline BRCA-mutated pancreatic cancer accounts for 6.2% of all cases.

Ruth March, Ph.D., senior vice president and head of Precision Medicine, Oncology R&D, AstraZeneca, commented:

The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing collaboration with Myriad to advance precision medicine for patients in need of new treatments. Patients with metastatic pancreatic cancer who test positive for germline-BRCA mutations can now access Lynparza, which is the first and only PARP inhibitor approved for this devastating disease.

Shares of AstraZeneca were up less than 1% early on Monday, at $50.54 in a 52-week range of $35.30 to $51.23. The consensus price target is $52.92.


Travel Cards Are Getting Too Good To Ignore

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.